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Objective. To evaluate the eﬃcacy and tolerability of a ﬁxed-dose combination of dexketoprofen and dicyclomine (DXD) injection
in patients with acute renal colic. Patients and Methods. Two hundred and seventeen patients were randomized to receive either
DXD (n = 109) or ﬁxed-dose combination of diclofenac and dicyclomine injection (DLD; n = 108), intramuscularly. Pain
intensity (PI) was self-evaluated by patients on visual analogue scale (VAS) at baseline and at 1, 2, 4, 6, and 8 hours. Eﬃcacy
parameters were proportion of responders, diﬀerence in PI (PID) at 8 hours, and sum of analogue of pain intensity diﬀerences
(SAPID). Tolerability was assessed by patients and physicians. Results. DXD showed superior eﬃcacy in terms of proportion of
responders (98.17% versus 81.48; P<0.0001), PID at 8 hours (P = 0.002), and SAPID0–8hours (P = 0.004). The clinical global
impression for change in pain was signiﬁcantly better for DXD than DLD. The incidence of adverse events was comparable in
both groups. However, global assessment of tolerability was rated signiﬁcantly better for DXD. Conclusion. DXD showed superior
eﬃcacy and tolerability than DLD in patients clinically diagnosed to be suﬀering from acute renal colic.
1.Introduction
Acute renal colic (ARC) is a common emergency condition
mimicking acute abdominal or pelvic condition. About
12% of the population is likely to suﬀer from ureteric
colic sometime in their lifetime and recurrence rates can
approach about 50% [1]. It is extremely important to relieve
the excruciating pain associated with this condition and2 Pain Research and Treatment
establish a conﬁrmatory radiological diagnosis at the earliest
onset.
The severe pain of ARC is due to increasing wall tension
in the urinary tract as a result of obstruction of the urinary
ﬂow. The rising pressure in renal pelvis stimulates release
of prostaglandins that cause vasodilatation. This leads to
diuresis and thus further increase in the intrapelvic pressure.
Prostaglandins also lead to ureteric spasm that further
amounts to pain [2, 3].
Parenteral nonsteroidal anti-inﬂammatory drugs
(NSAIDs) have been used widely for the treatment of ARC
and have been shown to achieve greater reduction in pain
scores than opioids. The use of NSAIDs has reduced the
requirement for further analgesia beyond short term [4].
Unlike opioids, NSAIDs not just symptomatically relieve
pain but also inhibit synthesis of prostaglandins, which are
involved in the etiopathogenesis.
Spasmolytics are traditionally used in renal colic, biliary
colic, or dysmenorrhoea for relief of smooth muscle spasm.
Asspasmolyticsrelievethepainassociatedwithsmoothmus-
cle spasm, the combination of NSAIDs with spasmolytics is
likely to be synergistic. Fixed dose of combinations (FDC)
of mefenamic acid, aceclofenac with spasmolytics such as
dicyclomine or drotaverine have been demonstrated to be
highly eﬀective in relief of acute spasmodic pain [5, 6]. In
the study performed by Pareek et al., addition of spasmolytic
such as drotaverine to aceclofenac was found to provide
signiﬁcant therapeutic beneﬁt as compared to monotherapy
with aceclofenac [6].
The parenteral formulation of dexketoprofen trometa-
mol, the S-enantiomer of ketoprofen, has shown good safety
and eﬃcacy in the treatment of ARC in previous studies
[3, 7]. The present study was planned to evaluate the eﬃcacy
and tolerability of FDC of an NSAID, dexketoprofen with
dicyclomine (DXD) injection in the treatment of clinically
diagnosedARCwhenadministeredasanintramuscular(IM)
injection. To our knowledge, this is the ﬁrst clinical study
reported for this FDC.
2. Patientsand Methods
2.1. Objective. The objective of this study was to compare
the eﬃcacy and tolerability of FDC of dexketoprofen and
dicyclomineIMinjection(DXD)withFDCofdiclofenacand
dicyclomine IM injection (DLD) in the treatment of patients
clinically diagnosed to be suﬀering from ARC.
2.2. Study Design. This was a randomised controlled, mul-
ticentric, open-label, parallel group study conducted at
diﬀerent centres across India. The study was approved by
institutional review board or independent ethics committee
for each centre. Written informed consent was provided
by each participant prior to any study-related procedure.
The execution and monitoring of the study were done in
accordance with the requirements of Good Clinical Practice.
2.3. Study Population. The study population involved male
and female patients between 18 and 65 years of age
presenting with acute colicky pain in the ﬂank and/or radi-
ating to the abdomen or genitalia. Patients with moderate
to severe pain on visual analogue scale (VAS ≥40mm) and
willing to provide written informed consent were included
in the study. The important exclusion criteria included
hypersensitivity to the study medications or intolerance to
NSAIDs or any anesthetic medication; active or suspected
gastrointestinal ulcer, chronic dyspepsia, or gastrointestinal
bleeding; Crohn’s disease or ulcerative colitis; history of
bronchial asthma, severe heart failure/moderate-to-severe
renal dysfunction (creatinine clearance <50mL/min.), or
severely impaired hepatic function (Child-Pugh score 10–
15); hemorrhagic diathesis and other coagulation disorders;
contraindication to use of NSAIDs; diagnosed gastrointesti-
nal obstruction; myasthenia gravis; glaucoma.
2.4. Treatment Procedure. Patients presenting with acute
colicky pain in the ﬂank region were screened based on
complete medical history and examination. Patients sat-
isfying the selection criteria were randomised to receive
either FDC of dexketoprofen (as trometamol) 50mg and
dicyclomine 20mg IM injection (DXD) [manufactured by
Emcure Pharmaceuticals Ltd., Pune] or FDC of diclofenac
(as sodium) 50mg and dicyclomine 20mg IM injection
(DLD) [from commercial source]. Patients were random-
ized in 1:1 ratio to “DXD” or “DLD” using blocks of
10 through online randomization software available at
http://www.randomization.com/. Any concomitant therapy
deemed necessary was provided for the patients as per
investigator’s discretion. However, any other analgesic, anti-
inﬂammatory, or muscle-relaxant therapy, and products
from alternative system of medicine with analgesic, anti-
inﬂammatory action were not allowed. The patients were
simultaneously investigated radiologically for renal pathol-
ogy.
2.5. Eﬃcacy Variables. The intensity of pain was assessed
f r o mV A Sa tb a s e l i n ea n da tt h ee n do f1 ,2 ,4 ,6 ,a n d8
hours after administration of study medication. At least 50%
i m p r o v e m e n ti np a i ns c o r ea t8h o u r sw a sc o n s i d e r e da st h e
responder’scriterion.Proportionofrespondersineachstudy
group was considered as primary eﬃcacy variable.
The secondary variables included pain intensity diﬀer-
ence (PID) after 8 hours of injection and sum analogue of
pain intensity diﬀerence (SAPID) over 8 hours.
PID was calculated for each observation by subtracting
the present PI from the baseline value. SAPID0–8 hours was
calculated as the weighted sum of the PIDs obtained from
t = +1 hour (hr) to t = 8 hours (hr) on VAS using
the following equation: SAPID =

[PIDt × time (hr)
elapsed since previous observation]. The secondary eﬃcacy
variablesalsoincludedassessmentforpatient’sclinicalglobal
impression for change in pain.
2.6. Tolerability Variables. Assessment of tolerability was
donebyrecordingpatient’sandphysicians’globalassessment
on tolerability of the drug and proportion of the patients
experiencing any drug-related adverse events.Pain Research and Treatment 3
Table 1: Demographic and baseline data.
FDC of
dexketoprofen
and dicyclomine
injection (DXD)
FDC of
diclofenac and
dicyclomine
injection (DLD)
P value∗
No of patients (n) 109 108 —
Age, years
(Mean ± SD) 34.54 ± 10.87 36.86 ±12.22 0.14
Sex (M:F) 79:30 68:40 0.15
Systolic BP, mm Hg
(Mean ± SD) 126.53 ±10.95 128.06 ±11.58 0.32
Diastolic BP, mm Hg
(Mean ± SD) 82.22 ±7.40 81.89 ±7.51 0.74
∗Fisher’stestappliedforproportionsandunpairedt-testfornumericaldata;
SD: standard deviation.
2.7. Statistical Analysis. Assuming responder rate of 0.7 in
control group, a sample size of 108 in each group had 80%
power to detect an increase of 0.16 with a signiﬁcance level
(alpha) of 0.05 (two-tailed; GraphPad StatMate 2.00). Fis-
cher’s exact test was applied to observe if there are signiﬁcant
diﬀerences between the responder rates. The decreases in PI
(VAS score), PID, and SAPID were calculated (Mean ± SD)
for each group and compared between the groups by using
unpaired t-test. The within-group comparison of VAS scores
was done using paired t-test. Tolerability was assessed by
evaluating the percentage of patients reporting side eﬀect.
Analysisofadverseeventsandglobalassessmentofsafetyand
eﬃcacy was done using Fisher’s exact test. For all statistical
tests, a P value of less than 0.05 was considered signiﬁcant.
3. Results
3.1. Patient Demography. Total 217 patients were recruited
andcompletedthestudyofwhich109patientsreceivedDXD
and 108 patients received DLD. The baseline demographic
data for both groups were comparable (Table 1). The clinical
diagnosis of acute renal colic was found to be consistent with
the radiological diagnosis of renal calculus in about 65%
patients in both groups.
3.2. Eﬃcacy. The baseline VAS scores were comparable
between the two groups (Table 1). There was a signiﬁcant
decrease in VAS scores as compared to baseline in both the
groups starting from 1 hour after administration of the study
drugs. The VAS score at the end of 6 hours and 8 hours was
signiﬁcantly less in DXD group as compared to DLD group
(P = 0.02 for 6hrs, P = 0.007 for 8hrs) (Figure 1, Table 2).
There were signiﬁcantly more responders (at least 50%
improvement in VAS) in DXD group (98.17%) compared to
DLD group (81.48%; P<0.0001). The SAPID and PID at
8th hour were signiﬁcantly more in DXD group compared to
DLD group (P = 0.004 and 0.002) (Table 2).
In the patient-reported clinical global impression for
change in pain, signiﬁcantly more (71.56%) patients in DXD
group demonstrated a “much better” response as compared
to DLD group (40.74%, P<0.0001). On the other hand,
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Figure 1: Improvements in VAS scores over 8 hours after DXD
and DLD injections; unpaired t-test applied for between-group
comparison.
Table 2: Eﬃcacy parameters for DXD and DLD injections.
Variables DXD (n = 109) DLD (n = 108) P value∗
Responder rate (%) 98.17 81.48 <0.0001
Baseline VAS,
(Mean ± SD) 81.97 ±11.68 80.47 ±12.44 0.36
VAS score at 8th hr,
(Mean ± SD) 12.46 ±15.18 19.35 ±21.47 0.007
PID at 8th hr,
(Mean ± SD) 69.51 ±18.69 61.12 ±20.00 0.002
SAPID,
(Mean ± SD) 480.91 ±156.67 420.35 ±146.67 0.004
VAS: visual analogue scale, PID: pain intensity diﬀerence, SAPID: sum of
painintensitydiﬀerence, ∗Fisher’stestappliedforproportionsandunpaired
t-test for numerical data, SD: standard deviation.
DLDgrouphadmorepatientswith“slightlybetter”response
as compared to DLD group (20.37% versus 0.92, P<
0.0001). All patients in DXD group had improvement in
pain, where as 2.78% patients in DLD group reported no
change in pain (Figure 2).
3.3. Tolerability. The adverse events reported with DXD and
DLD are depicted in Table 3. The incidence of vomiting and
nausea occurred in relatively higher number of patients in
DLD group. Incidence of all the other adverse events was
comparable between the two groups.
On patients’ global assessment of tolerability, signiﬁ-
cantly more patients in DXD group rated the tolerabil-
ity as good or very good (98.17% versus 75.92%; P<
0.0001) (Figure 3(a)). Similarly, 98.17% physicians reported
favourable tolerability of DXD as compared to 77.78% for
DLD (P<0.0001) (Figure 3(b)).
4. Discussion
The analgesic and anti-inﬂammatory activity of ketoprofen
is limited to its S(+)enantiomer or dexketoprofen and the
R(−)enantiomer is devoid of any such activity. Use of
dexketoprofen in place of ketoprofen oﬀers distinct beneﬁts4 Pain Research and Treatment
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Figure 2: Patient-reported clinical global impression for change in
pain.Fisher’sexacttestappliedbetweenproportion[(muchworse+
worse + slightly worse + no change) versus (slightly better + better
+ much better)].
Table 3: Adverse events (ITT analysis).
Adverse event (DXD); % (n)
(n = 109)
(DLD); % (n)
(n = 108) P value∗
Total no. of patients 11.93(13) 12.04 (13) 1.00
Burning micturition 2.75 (3) 0.93 (1) 0.62
Pain at injection site 2.75 (3) 0 (0) 0.25
Headache 1.83 (2) 0.93 (1) 1.00
Nausea 1.83 (2) 7.40(8) 0.06
Dryness of mouth 1.83 (2) 0 (0) 0.5
Generalised
weakness 1.83 (2) 0.93 (1) 1.00
Giddiness 0.92 (1) 0.93 (1) 1.00
Weakness 0.92 (1) 0(0) 1.00
Cough 0 (0) 0.93 (1) 0.5
Vomiting 0 (0) 4.63 (5) 0.03
∗Fisher’s exact test ITT: Intention to treat.
such as same analgesic eﬀect at lower doses, avoidance of
excess metabolic load, and lack of adverse eﬀects or drug
interactions due to R-enantiomers [8, 9].
Oral dexketoprofen has been shown to have faster onset
of analgesia than several other NSAIDs. Tromethamine salt
of dexketoprofen is highly water soluble, which allows rapid
and almost complete absorption of dexketoprofen [8]. Oral
dexketoprofen is a ﬁrst-line drug used for the treatment of
mild-to-moderate acute pain and has shown its comparable
eﬃcacyaswellasbettertolerabilitythanketoprofeninseveral
pain models such as dental pain, dysmenorrhea, and back
pain [8, 10]. Parenteral administration of dexketoprofen has
shown eﬃcacy in reducing acute abdominal pain such as
renal colic [3] and postoperative pain following hernia repair
surgery [11]. Intramuscular dexketoprofen 50mg was found
tohavefaster,better,andlongeranalgesiathanintramuscular
diclofenac 50mg [11].
NSAIDs are commonly used in clinical practice in
combination with antispasmodics. Use of injectable NSAIDs
andantispasmodicsinARCcansubsidetheacutepainaswell
as reduce oedema and inﬂammation at the site of ureteric
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Figure 3: (a) Patient’s global assessment of tolerability, (b)
Physician’s global assessment of tolerability. Fisher’s extract test
applied between proportions [(very good + good) versus (fair +
unchanged)].
obstruction. It has been shown that addition of spasmolytic
adds to the eﬃcacy of NSAID in the treatment of acute
spasmodic pain [6]. However, there are very few published
studies assessing the safety and eﬃcacy of such combinations
andsuperiorityofonecombinationoveranother.Theresults
of the present study demonstrate that FDC of dexketoprofen
and dicyclomine injection has better eﬃcacy in reduction
of ARC than FDC of diclofenac and dicyclomine injection,
a commonly used FDC for acute spasmodic pain. The
responder rate for DXD was more than 98% and the degree
of analgesia achieved was signiﬁcantly better than DLD.
This was translated into signiﬁcantly better patient-reported
clinical global impression for change in pain. The results
of this study were consistent with the results of a previous
study on injectable dexketoprofen, which also showed better
eﬃcacy than diclofenac in the treatment of postoperative
pain [11].
DXD was well tolerated as compared to DLD with more
than 98% patients and physicians reporting good or very
good tolerability for DXD as compared to 75–77% for DLD.
DXD was also found to cause less incidence of vomitingPain Research and Treatment 5
thanDLD.However,thetotalincidenceofadverseeventswas
comparable for DXD and DLD.
This study had a potential limitation that it was open-
label, which could introduce bias. However, patients were
not aware of the speciﬁc medication in the injection syringe,
assuring unbiased response. In this study, we used diclofenac
50mginsteadof75mgasthecommerciallyavailableFDCsof
diclofenac with dicyclomine in the country contain no more
than 50mg of diclofenac.
5. Conclusion
This ﬁrst report on the ﬁxed-dose combination of dexketo-
profen and dicyclomine injection shows that this product
has superior eﬃcacy and tolerability than the ﬁxed-dose
combination of diclofenac and dicyclomine injection in
patients clinically diagnosed to be suﬀering from acute renal
colic.
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